CAR-T therapy patients monitored for years in new safety study
Knowledge-focused
ENROLLING_BY_INVITATION
This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC